2026 NPPES data Pulmonary Disease Physician NPI 1912360686
Verify on CMS →

LIJO ILLIPPARAMBIL

Pulmonary Disease Physician in PHILADELPHIA, Pennsylvania. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
419
Medicare Part D claims · 89 beneficiaries · Pulmonary Disease Physician avg: 1K
Generic prescribing
29%
generic claims · 71% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
76.7036/100
▼ 6 pts below national avg 83.1 · [object Object]
Industry payments
$26.44
1 payments · CMS Open Payments (Sunshine Act)

What the federal data shows

LIJO ILLIPPARAMBIL reported a CMS MIPS final score of 76.7036/100 — below the 83.1 national average — and filed 419 Medicare Part D claims in 2023.

76.7036/100
MIPS score · -6 vs avg
419
Part D claims, 2023
29%
generic prescribing
Likely
board-certified (heuristic)

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

LIJO ILLIPPARAMBIL's MIPS score vs every scored U.S. clinician

CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure

77 21st percentile higher than 21% of 477,587 scored providers

0–10: 8,684 scored providers (2%). Below this entry. 10–20: 3,008 scored providers (1%). Below this entry. 20–30: 3,069 scored providers (1%). Below this entry. 30–40: 2,746 scored providers (1%). Below this entry. 40–50: 2,928 scored providers (1%). Below this entry. 50–60: 5,882 scored providers (1%). Below this entry. 60–70: 13,906 scored providers (3%). Below this entry. 70–80: 118,074 scored providers (25%). This entry sits in this band. 80–90: 129,887 scored providers (27%). Above this entry. 90–100: 189,403 scored providers (40%). Above this entry. This provider 0 100 every MIPS-scored clinician, bucketed by value

Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Merit-based Incentive Payment System (MIPS) · 2023

Board certification likely (heuristic — not verified)

LIJO ILLIPPARAMBIL practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

What does the federal data show about LIJO ILLIPPARAMBIL?

Below national average

NPI registry status

Active

Issued 03/31/2016

NPI 1912360686

Primary specialty

Pulmonary Disease Physician

Mid-sized

9,271 US NPIs in this specialty

Medicare Part D claims

419 71% vs specialty avg

2023 prescription claims

Specialty avg: 1,457

MIPS final score

76.7036/100 6.3964% pts

Above neutral band

vs 83.1 national avg

Specialty distribution in Pennsylvania

How Pulmonary Disease Physician compares to other specialties among Pennsylvania providers

Pennsylvania providers

Pulmonary Disease Physician share within Pennsylvania

1. Pulmonary Disease Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Pulmonary Disease Physician share within Pennsylvania

Medicare quality performance — MIPS

LIJO ILLIPPARAMBIL's 2023 MIPS final score plotted against the Pulmonary Disease Physician national average

Below national average
MIPS Final Score
76.7036/100
vs 83.1 national avg · 2023 performance year

MIPS final score (Pulmonary Disease Physician) — 76.7036/100 vs national avg 83.1

0%100%National avg83%76.7%
MIPS final score (Pulmonary Disease Physician) — 76.7036/100 vs national avg 83.1

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

LIJO ILLIPPARAMBIL is a Pulmonary Disease Physician provider practicing in PHILADELPHIA, Pennsylvania, according to the CMS National Plan and Provider Enumeration System (NPPES). NPI: 1912360686. This profile includes practice location, specialty classification, and organizational affiliations from the CMS provider registry. Provider information is self-reported to CMS and updated monthly.

LIJO ILLIPPARAMBIL appears in the CMS NPPES registry as a Pulmonary Disease Physician provider at 3401 N BROAD ST, PHILADELPHIA, PA, 19140, with a listed phone of (157) 075-8642. NPI 1912360686 was issued on 03/31/2016. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what ILLIPPARAMBIL most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 419 prescription claims written by this provider, covering 89 Medicare beneficiaries and totaling roughly $219K in drug spend, split 71% brand-name and 29% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 76.7036/100 for the 2023 performance year (Quality 55.1936, Cost 54.937), compared with the national average of 83.1.

Pulmonary Disease Physician is a mid-sized specialty nationwide, with 9,271 enrolled providers across 53 states and an average of 1,457 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

3401 N BROAD ST
PHILADELPHIA, PA 19140

Provider Details

NPI 1912360686
Specialty Pulmonary Disease Physician
Gender Male
NPI Issued 03/31/2016

CMS Quality Score (MIPS)

Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.

76.7036
Final Score
Avg: 83.1
55.1936
Quality
54.937
Cost
98
Promoting Interoperability

Reporting: Group practice

Hospital and facility affiliations

Facilities where LIJO ILLIPPARAMBIL bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.

TEMPLE FACULTY PRACTICE PLAN INC
PHILADELPHIA, PA

Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for LIJO ILLIPPARAMBIL. Source: openpaymentsdata.cms.gov.

Total received

$26

Largest payer

Tactile Systems Technology Inc

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

License & disciplinary context — Pennsylvania PA-BOM 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~45K Pennsylvania medical licensees in 2023 — they are NOT specific to LIJO ILLIPPARAMBIL. To verify LIJO ILLIPPARAMBIL's current license status, search the PA-BOM public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

133
Total board actions, Pennsylvania 2023
Across 129 cases
2.96
Actions per 1,000 licensees
Pennsylvania statewide rate
probation
Most common action type
48 cases

PA-BOM publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Pennsylvania disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Brand-heavy

LIJO ILLIPPARAMBIL — brand share 71.0%
Specialty average (est.)

71% brand-name claims vs 29% generic, on 419 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

419
Total Claims
$219K
Total Drug Cost
89
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
480
Total Day Supply
13,535
Brand vs Generic
71% brand / 29% generic
Brand Drug Cost
$187K
Generic Drug Cost
$32K
Antibiotic Claims
11

Patient Demographics

Average Patient Age
68.6 years
Avg HCC Risk Score
2.00
Gender Split
65% female / 35% male
Age Distribution
<65: 24, 65-74: 43, 75-84: N/A, 85+: N/A

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

Drug Claims
Albuterol Sulfate Hfa
Albuterol Sulfate
77
Trelegy Ellipta
Fluticasone/Umeclidin/Vilanter
72
Symbicort
Budesonide/Formoterol Fumarate
46
Stiolto Respimat
Tiotropium Br/Olodaterol Hcl
22
Famotidine
20
Prednisone
18
Fluticasone-Vilanterol
Fluticasone/Vilanterol
16
Anoro Ellipta
Umeclidinium Brm/Vilanterol Tr
14
Advair Diskus
Fluticasone Propion/Salmeterol
12
Breo Ellipta
Fluticasone/Vilanterol
11

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Pulmonary Disease Physician Overview

How LIJO ILLIPPARAMBIL fits within the Pulmonary Disease Physician landscape nationally.

9,271
Pulmonary Disease Physician Providers in US
53
States with Pulmonary Disease Physician
1,457
Avg Claims per Provider

LIJO ILLIPPARAMBIL's 419 claims are below the specialty average of 1,457.

Nearby Pulmonary Disease Physician Providers in Pennsylvania

Other clinicians with the same primary specialty enrolled in Pennsylvania, drawn from the same CMS NPPES roster as ILLIPPARAMBIL.

Compare Pulmonary Disease Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is LIJO ILLIPPARAMBIL's specialty?
LIJO ILLIPPARAMBIL specializes in Pulmonary Disease Physician and practices in PHILADELPHIA, Pennsylvania.
How much does LIJO ILLIPPARAMBIL prescribe under Medicare Part D?
In 2023, LIJO ILLIPPARAMBIL wrote 419 Medicare Part D claims totaling $219K in drug costs for 89 beneficiaries.
What is LIJO ILLIPPARAMBIL's Medicare quality score?
LIJO ILLIPPARAMBIL has a CMS MIPS Final Score of 76.7036/100 (Quality: 55.1936, Cost: 54.937). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is LIJO ILLIPPARAMBIL located?
LIJO ILLIPPARAMBIL is located at 3401 N BROAD ST, PHILADELPHIA, PA, 19140. Phone: (157) 075-8642.
What is LIJO ILLIPPARAMBIL's NPI number?
LIJO ILLIPPARAMBIL's National Provider Identifier (NPI) is 1912360686, issued on 03/31/2016.
Does LIJO ILLIPPARAMBIL prescribe more brand-name or generic drugs?
LIJO ILLIPPARAMBIL's prescribing is 71% brand-name and 29% generic drugs by claim count, with $187K in brand drug costs.
How many Pulmonary Disease Physician providers are there in the US?
There are 9,271 Pulmonary Disease Physician providers across 53 states in the US. The average Pulmonary Disease Physician provider writes 1,457 Medicare Part D claims per year.
What drugs does LIJO ILLIPPARAMBIL prescribe most often?
Based on 2023 Medicare Part D data, LIJO ILLIPPARAMBIL's most frequently prescribed drugs include Albuterol Sulfate Hfa, Trelegy Ellipta, Symbicort. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does LIJO ILLIPPARAMBIL accept Medicare?
LIJO ILLIPPARAMBIL appears in CMS Medicare data with 419 Part D claims and 89 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify LIJO ILLIPPARAMBIL's credentials?
LIJO ILLIPPARAMBIL's NPI is 1912360686. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Quality Performance
CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology